@ThePTCTC#Tandem24 Fertiltiy in Long term survivors of HCT Key concepts by Dr Karen Burns discussion of infertility is important.. concept of CED in calculating risk
Long time in the making: 5 year survival outcomes for pediatric stem cell transplant patients requiring intensive care. Grateful to everyone who helped with this project. @CIBMTR@BloodAdvances@ThePTCTC@ASTCT@UCSF@UCSFChildrens https://t.co/VGqsOpGLlq
📢 Not one but TWO #GeneTherapy products approved for #SickleCell disease by the @US_FDA 👏
Medicine will never be the same again. Now let's make these treatments AFFORDABLE and ACCESSIBLE to all who need them.
https://t.co/LTFOuRfgvd
Did you ever wonder why our marrow is located inside of our *bones*, #MedTwitter? There’s no a priori anatomical reason it should be sited there. Blood cells could form in our spleens & livers, as they do during our fetal lives; or elsewhere, as in some animals. Let’s discuss! /1
🚨PubAlert🚨 we show how #MachineLearning can be used to leverage longitudinal data collected directly from the medical records after allo HCT to predict survival in patients. https://t.co/HbUldtqCkF
https://t.co/JIXZcMfBGK. Join us tommorow at 2pm EST as 🇧🇷 @CarmemBonfim1 presents @Duke_Childrens@ThePTCTC seminar. Dr Bonfim will speak on Brazils Haplo experience in non malignant disease.
Fertility Basics for the Peds BMT patients.. chaired by @SethRotz@ThePTCTC @BeTheMatch #HCT. Nice overview of fertility preservation options for our patients prior to #HCT Gene therapy, things we need2 know. Webinar by Dr. Allison Close, see link below https://t.co/DBpijqt47S
Listened 2 an inspiring talk by Prof Mamta VijayManglani @ 2nd Emirates peds bmt conference Govt hospital Mumbai, Borivalli BMT center median cost Allo 9184$, auto 2487$ #hct for the poor & the masses! 300 & counting....that's what I call impact..#HCT for all who need it
With CRISPR-Cas9, a repressor of fetal hemoglobin expression was disrupted in hematopoietic stem cells from three persons with sickle cell disease. Edited cells were reinfused. Hematopoiesis was restored. Read the full study results: https://t.co/wa3S5ZdpsA
In this trial, 1-year GVHD-free, relapse-free survival after stem-cell transplantation was 52.7% in the cyclophosphamide–tacrolimus–mycophenolate mofetil group and 34.9% in the tacrolimus–methotrexate group. https://t.co/wCdvP1LChu
Emapalumab can lead to good transplant outcomes for STAT1 GOF. Next step incorporating into conditioning for primary immune regulatory disorders. See our paper in JACI (https://t.co/3GTiRwQVuU) and details about our trial open at
@MSKCancerCenter
(https://t.co/cuDbgttart…)
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. HLA-haploidentical BMT with PTCy as upfront therapy in patients with SAA results in survival >90% and low morbidity/mortality.
https://t.co/2cNEJP8pMJ
Today is #WorldSickleCellDay#WSCD23#SickleCellDisease has been a priority for this Journal in the past years and the result is a Commission that will be officially launched on July 12, 9.30 – 11am East Africa Time at a hybrid event ⬇️
Register at https://t.co/QQsmI0vin1
Happy to share this recent publication in @cytotherapy that features a global perspective on gene therapy clinical trials for beta hemoglobinopathy. Also delighted to see content from South America 🇧🇷 @dvandersonrocha@samuelcfcouto
https://t.co/fMJwcekEH4
Ahead of #WorldSickleCellDay#WSCD23 we are publishing the first detailed global estimates on the burden of #sicklecell disease
Read it #openaccess https://t.co/pVlWZ6s1G4
The authors show that mortality linked to #sicklecell disease is higher than previously described🧵
With early (<100d) CD4+ AND B-cell reconstitution after #BMT higher survival chances AND dramatically LOWER #GVHD Thanks team: @prinsesmaximac@StJude and @MSKCancerCenter for fruitful collab! More to come!! https://t.co/nIrM1yTN5g
A randomized controlled trial with extracorporeal photopheresis as #GVHD prophylaxis found it does not prevent GVHD and prophylactic extracorporeal photopheresis does not affect survival. Read the full #openaccess article: https://t.co/XCw7fFxrvh